Trial Profile
Targeting SPMS: Effect of teriflunomide treatment on microglial activation in an MS patient cohort at risk of progression. A [11C]PK11195 Brain PET study
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 17 Mar 2023
Price :
$35
*
At a glance
- Drugs Teriflunomide (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms TERIPET
- 15 Mar 2023 Planned primary completion date changed from 1 Nov 2022 to 1 Dec 2023.
- 31 May 2022 Status changed from recruiting to active, no longer recruiting.
- 07 Feb 2018 Status changed from not yet recruiting to recruiting.